DKSH and BMT Sign Strategic Partnership to Provide Early Lung Cancer Detection Device to Patients in Korea November 05, 2021


			
				DKSH and BMT Sign Strategic Partnership to Provide Early Lung Cancer Detection Device to Patients in Korea

The partnership will ensure patient-oriented healthcare services are provided to patients in domestic and overseas pharmaceutical and medical device markets.

Media release 

DKSH and BMT Sign Strategic Partnership to Provide Early Lung Cancer Detection Device to Patients in Korea

The partnership will ensure patient-oriented healthcare services are provided to patients in domestic and overseas pharmaceutical and medical device markets.

Seoul, November 5, 2021 – DKSH Korea’s Business Unit Healthcare, Asia Pacific’s leading partner for healthcare companies seeking to grow their business, and Biometrics Technology (BMT) have entered a strategic agreement to expand BMT’s presence of medical device and pharmaceutical products to patients in Korea and Asia Pacific.

 

As part of this strategic partnership, signed at DKSH’s headquarters in Gangnam, Seoul, DKSH will be supporting BMT to enhance market reach and market penetration of the world’s first medical device that is able to diagnose early-stage lung cancer.

 

In many countries across Europe and in the United States, patients’ quality of life is improving through the accurate and early diagnosis of lung cancer thanks to medical devices that enable early detection and hence early treatment and intervention. Early detection and patient centricity are at the core of BMT’s mission.

 

Through this partnership, two companies plan to accelerate specialized patient support in the domestic medical device market. Furthermore, the two companies plan to cooperate in entering the medical devices and diagnostics market in Southeast Asia in the future.

 

Tae-Seon Kim, CEO of BMT, said: “Through the technology of autoantibody analysis, BMT developed the world’s first lung cancer diagnosis device for stage 0-1 lung cancer. We look forward to providing this technology to patients not only in Korea but beyond our borders, thanks to DKSH’s market expansion services. We are also working towards providing innovation in diagnostics and early detection for breast cancer, colorectal cancer, and pancreatic cancer among others, with the aim to become the market leader in cancer diagnosis in the near future.

 

Danny Lee, General Manager, Business Unit Healthcare, DKSH Korea, said: "This partnership reflects DKSH’s patient-centric approach and is in line with our mission to provide quality healthcare to patients across Asia Pacific. Competition in the medical device industry is intensifying, and we will ensure that BMT can differentiate their product offering by combining their outstanding products with our unrivalled market access.”

 

The ceremony was attended by executives from both companies, including Tae-Sun Kim, CEO of BMT, and Danny Lee, GM of DKSH Healthcare.